Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Nuvaxovid JN.1 dispersion for injection in pre-filled syringe {equilateral_black_triangle}

Active Ingredient:
SARS-CoV-2 recombinant spike protein
Company:  
SANOFI See contact details
ATC code: 
J07BN04
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Product Information
{arrow_left}
{arrow_right}
{healthcare_pro_orange} For Healthcare Professionals

A Change of Ownership application has been approved by the MHRA to transfer the licence for Nuvaxovid (COVID-19 Vaccine (recombinant, adjuvanted)) from Novavax CZ a.s. to Aventis Pharma Limited (trading as Sanofi). The approved Sanofi SmPC and PIL for Nuvaxovid JN.1 dispersion for injection in pre-filled syringe are provided here for ease of reference.

SANOFI
Company image
Address
Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Medical Information e-mail
[email protected]
Medical Information Direct Line
+44 (0)800 035 2525
Telephone
+44 (0)118 354 3000